186
Participants
Start Date
June 18, 2020
Primary Completion Date
June 11, 2024
Study Completion Date
June 11, 2024
Atogepant 60 mg
Tablets containing 60 mg atogepant
Takanoko Hospital /ID# 232723, Matsuyama
Fukuiken Saiseikai Hospital /ID# 232988, Fukui-shi
Duplicate_Higashi Sapporo Neurology and Neurosurgery Clinic /ID# 232710, Sapporo
Konan Medical Center /ID# 232922, Kobe
Mito Kyodo General Hospital /ID# 232990, Mito
Atsuchi Neurosurgical Hospital /ID# 232907, Kagoshima
Duplicate_Tokai University Hospital /ID# 233071, Isehara-shi
Fujitsu Clinic /ID# 232717, Kawasaki-shi
Umenotsuji Clinic /ID# 232675, Kochi
Sendai Headache and Neurology Clinic Medical Corporation /ID# 232677, Sendai
Saitama Medical University Hospital /ID# 233017, Iruma-gun
Saitama Neuropsychiatric Institute /Id# 232711, Saitama-shi
Japanese Red Cross Shizuoka Hospital /ID# 232992, Shizuoka
Duplicate_Dokkyo Medical University Hospital /ID# 232995, Shimotsuga-gun
Niwa Family Clinic /ID# 232713, Chofu-shi
Duplicate_Tokyo Headache Clinic /ID# 232715, Shibuya-ku
Keio University Hospital /ID# 233030, Shinjuku-ku
Duplicate_Nagaseki Headache Clinic /ID# 232719, Kai-shi
DOI Internal Medicine-Neurology Clinic /ID# 232722, Hiroshima
Hiroshima Neurology Clinic /ID# 232720, Hiroshima
Tanaka Neurosurgical Clinic /ID# 232884, Kagoshima
Tatsuoka Neurology Clinic /ID# 232912, Kyoto
Tominaga Hospital /ID# 232909, Osaka
Shinagawa Strings Clinic /ID# 232908, Tokyo
Lead Sponsor
AbbVie
INDUSTRY